Herpes Zoster Epidemiology Forecast 2025-2034

Herpes zoster, commonly known as shingles, occurs in about 1.2 to 3.4 per 1,000 healthy younger people each year. In people over 65, the incidence ranges from 3.9 to 11.8 cases per 1,000 each year. Recurrences are observed to be the most prevalent in people with weakened immune systems.

Herpes Zoster Epidemiology Forecast Report Coverage

The “Herpes Zoster Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of herpes zoster. It projects the future incidence and prevalence rates of herpes zoster across various populations. The study covers age and type as major determinants of the herpes zoster-affected population. The report highlights patterns in the prevalence of herpes zoster over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of herpes zoster in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Herpes Zoster: Disease Overview

Herpes zoster is a viral infection caused by the reactivation of the varicella-zoster virus. It is the same virus that causes chickenpox and is known to remain dormant in the nervous system, reactivating years later as herpes zoster. The condition is characterized by pain, burning, or tingling sensations followed by a rash that appears as blisters. Some patients may also experience fever, headache, and fatigue. Shingles can be more severe in people with weakened immune systems.

Herpes Zoster: Treatment Overview

The treatment for herpes zoster generally includes antiviral medications, pain management, and supportive care. Antiviral medications, such as acyclovir, valacyclovir, or famciclovir, are prescribed to reduce the severity and duration of the infection. Over-the-counter pain relievers (acetaminophen or ibuprofen) are typically taken for managing pain associated with shingles. In some cases, doctors may prescribe stronger pain medications (opioids or specific pain-relief medications like gabapentin or pregabalin).

Epidemiology

The herpes zoster epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for herpes zoster by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for herpes zoster and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Herpes zoster occurs in 1.2 to 3.4 per 1,000 healthy younger individuals annually, while the incidence rises to 3.9 to 11.8 per 1,000 among people over 65.
• The risk of herpes zoster is linked to advancing age, with about 50% of all cases occurring in people over the age of 50.
• It is estimated that nearly 10% of individuals who have had chickenpox will develop shingles later in life.
• Around 25% of people with HIV and 7% to 9% of individuals who have received renal or cardiac transplants experience shingles.

Country-wise Herpes Zoster Epidemiology

The herpes zoster epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of herpes zoster varies significantly between countries due to differences in the prevalence of varicella (chickenpox), vaccination rates, immune system health, age demographics, healthcare systems, and access to antiviral treatments. In the United States, approximately 1 million cases of herpes zoster or shingles are diagnosed annually.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of herpes zoster based on several factors.
• The Herpes Zoster Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of herpes zoster are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of herpes zoster epidemiology in the 8 major markets?
• What will be the total number of patients with herpes zoster across the 8 major markets during the forecast period?
• What was the country-wise prevalence of herpes zoster in the 8 major markets in the historical period?
• Which country will have the highest number of herpes zoster patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of herpes zoster during the forecast period of 2025-2034?
• What are the currently available treatments for herpes zoster?
• What are the disease risks, signs, symptoms, and unmet needs of herpes zoster?

This product will be delivered within 3-5 business days.